CLOs on the Move


 
Our mission at Aveda is to care for the world we live in, from the products we make to the ways in which we give back to society.
  • Number of Employees: 0-25
  • Annual Revenue: > $1 Billion
  • www.aveda.com
  • 4000 Pheasant Ridge Dr NE
    Minneapolis, MN USA 55449-7101
  • Phone: 866.823.1425

Executives

Name Title Contact Details

Similar Companies

Lakeridge Health

Lakeridge Health is one of the leading companies in Healthcare, Pharmaceuticals, & Biotech industry. Lakeridge Health is based in Oshawa, ON. You can find more information on Lakeridge Health at www.lakeridgehealth.on.ca

Integrated Recovery Products

Integrated Recovery Products is a Costa Mesa, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Watson Clinic

Watson Clinic is one of the leading companies in Healthcare, Pharmaceuticals, & Biotech industry. Watson Clinic is based in Lakeland, FL. You can find more information on Watson Clinic at www.watsonclinic.com

Symbiomix Therapeutics

Symbiomix (sim-bye-OH-mix) is a late-stage, privately held biopharmaceutical company developing innovative medicines for serious women`s health infections that have been long neglected and are in need of new therapeutic options. Symbiomix was founded in 2012 by a team of experienced industry professionals and entrepreneurs and is backed by three of the world`s leading healthcare venture capital firms, OrbiMed, Fidelity Biosciences and HBM Partners. The Company`s lead product is SYM-1219, a novel drug candidate containing secnidazole, which is a next generation 5-nitroimidazole antibiotic. Symbiomix is based in New Jersey, with additional offices in Maryland and Connecticut.

MolecularMD

MolecularMD founders Brian Druker (lead clinical investigator for Gleevec, the first molecularly-targeted anticancer agent) and Sheridan G. Snyder (entrepreneur, founder of Genzyme and Upstate Biotechnology) came together with the mission of providing precise, standardized molecular testing for new oncology drugs. The company’s initial accomplishment was in developing and implementing the only standardized assay for quantification of BCR-ABL expression levels, which proved critical to pharmaceutical sponsors in satisfying regulators for approval of the second-generation ABL kinase inhibitors nilotinib (Tasigna, Novartis) and dasatinib (Sprycel, BMS). With that foundational success in supporting pivotal international studies with centralized, high-quality diagnostic services, MolecularMD has become a preferred provider of molecular diagnostics products and services to pharmaceutical and biotech drug developers. Capabilities range from specialty molecular testing services performed in MolecularMD’s centralized CLIA-certified and CAP-accredited laboratory, to development of FDA approved companion diagnostics to support new drug registrations.